Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reverse Transcriptase Inhibitors in Psoriasis
NCT04274595Completed
- Sponsor
- CHU Nîmes
- Start
- Feb 2020
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of emtricitabine and tenofovir disoproxil fumarate in plaque psoriasis, sponsored by CHU Nîmes. Primary endpoint: Percentage of patients no longer presenting S9.6:D5H6 RNA:DNA duplex at Day 7. Started Feb 2020; status: completed.
02
Drugs
emtricitabinetenofovir disoproxil fumarate
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT04274595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04274595.